DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  

Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile

 

Amgen 

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


SEARCH JOBS

View Clinical Trials from BioPharm Insight





Collaborations

Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display





 Company News
Amgen (AMGN)'s First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion 4/23/2014 6:41:22 AM    More...
Amgen (AMGN)'s Heart Failure Drug Ivabradine Wins Fast Track Status From The FDA 4/18/2014 8:01:01 AM    More...
Amgen (AMGN) Announces Webcast Of 2014 First Quarter Financial Results 4/18/2014 6:15:52 AM    More...
Amgen (AMGN)'s Melanoma Drug Talimogene Laherparepvec Misses Phase 3 Goals 4/4/2014 7:54:26 AM    More...
Amgen (AMGN) Spends $270 Million To Exit Osteporosis Pact With GlaxoSmithKline (GSK) 4/4/2014 6:10:45 AM    More...
Amgen (AMGN)'s Evolocumab Lowers Cholesterol Up To 66 Percent In Pivotal Phase 3 Studies 3/31/2014 7:16:10 AM    More...
NeuroSigma, Inc. Signs On Two Former Amgen (AMGN) Finance Executives 3/28/2014 6:20:07 AM    More...
Amgen (AMGN) To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session 3/27/2014 6:35:46 AM    More...
Phase 3 Pivotal Data On Amgen (AMGN)'s Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session 3/25/2014 6:56:56 AM    More...
Amgen (AMGN) Drug Meets Phase 3 Goals For Those With High Genetic Cholesterol 3/17/2014 8:21:12 AM    More...
12345678910...